UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 4, 2009
Inverness Medical Innovations, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
001-16789
|
|
04-3565120 |
|
|
|
|
|
|
| (State or other jurisdiction
|
|
(Commission file number)
|
|
(IRS Employer |
| of incorporation)
|
|
|
|
Identification No.) |
51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453
(Address of principal executive offices)
Registrant’s telephone number, including area code: (781) 647-3900
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
The staff of the United States Securities and Exchange Commission has completed its review of our
annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2008 (the “10-K”) and
our definitive proxy statement for our 2009 annual meeting of stockholders (the “2009 Proxy
Statement”), which we announced on September 22, 2009. No restatements or amendments of the 10-K,
the 2009 Proxy Statement or any past financial statements were
required, nor are any prospective
changes to the Company’s accounting practices anticipated as a result of the review.